The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction.

Conditions

heart failure with moderately reduced ejection fraction (HFmrEF)

Brief summary

Change in left ventricular end-systolic volume after 12 months of treatment as measured by MRI.

Detailed description

Change in left ventricular end-diastolic volume measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in indexed left ventricular end-systolic and end-diastolic volumes measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in left ventricular ejection fraction measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Death from cardiovascular causes or first hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes or first or subsequent hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes in patients with ischemic HFmrEF over a 12 month treatment period., First hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period., First or subsequent hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period., Number of days until death from cardiovascular causes or first hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period., All-cause death in patients with ischemic HFmrEF over a 12 month treatment period.

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGVALSARTAN AND SACUBITRIL

DRUGRAMIPRIL

DRUGPlacebo to VALSARTAN AND SACUBITRIL PL1 PL2

DRUGPlacebo to RAMIPRIL PL3 PL4

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in left ventricular end-systolic volume after 12 months of treatment as measured by MRI.	—

Secondary

Measure	Time frame
Change in left ventricular end-diastolic volume measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in indexed left ventricular end-systolic and end-diastolic volumes measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in left ventricular ejection fraction measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Death from cardiovascular causes or first hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes or first or subsequent hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes in patients with ischemic HFmrEF over a 12 month treatment period., First hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period., First or subsequent hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period.	—

Measure

Time frame

Change in left ventricular end-diastolic volume measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in indexed left ventricular end-systolic and end-diastolic volumes measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Change in left ventricular ejection fraction measured by MRI in patients with ischemic HFmrEF after 12 months of treatment., Death from cardiovascular causes or first hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes or first or subsequent hospitalization due to HF in patients with ischemic HFmrEF over a 12 month treatment period., Death from cardiovascular causes in patients with ischemic HFmrEF over a 12 month treatment period., First hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period., First or subsequent hospitalization for HF in patients with ischemic HFmrEF over a 12 month treatment period.

—

Countries

Poland

Outcome results

None listed